Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
12:48pWhat's next for #biopharma Q3 earnings
1
12:46pMaxim Group Reiterates “Hold” Rating for Gilead Sciences, Inc. $GILD  
12:42p$GILD - Maxim Group Reiterates "Hold" Rating for Gilead Sciences, Inc. #GILD .. 
10:59aMarshall Wace LLP Acquires Shares of 161,801 Gilead Sciences, Inc. $GILD  
10/22Gilead Science’s exec chairman talks in an interview about the new era of bio..
4
10/22$GILD - Gilead Sciences' #GILD "Hold" Rating Reiterated at Maxim Group  
10/22
1
10/22Here's a list of the most important companies reporting earnings this week: $..
21
10/22ZWJ Investment Counsel Inc. Has $22.56 Million Holdings in Gilead Sciences, I.. 
10/22Gilead Sciences, Inc. $GILD Position Held by Palisades Hudson Asset Managemen.. 
10/21$GILD a two month consolidation into earnings (Thurs AMC) 
10/21Time To Trust Gilead Again  
10/21KBC Group NV Cuts Stake in Gilead Sciences, Inc. $GILD  
10/21Gilead Sciences $GILD Receiving Somewhat Favorable Press Coverage, Report Sho.. 
10/21Gilead Sciences, Inc. $GILD Given a $96.00 Price Target by Berenberg Bank Ana.. 
10/21Gilead Sciences, Inc. $GILD Given Hold Rating at Maxim Group  
10/20$GILD held its 10-week (and 50-day) well this week. Continues to look like co..
2
10/20Gilead Sciences's hold rating reiterated at BMO Capital Markets. $82.00 PT.  
10/20BMO Capital Keeps a Hold Rating on Gilead Sciences $GILD  
10/20  
10/20"Like Novartis’s therapy, which was priced at $475k, Gilead’s treatment comma..
4
10/2050 most #liquid, high #RelativeStrength #stocks in the #market $AABA $BABA $B.. 
10/20#gold #price GoldMarketNews.EU Celgene Could Be the Best CAR-T Stock to Buy, .. 
10/20Why This Pharma May be the Best CAR-T Bet, Not Gilead
1
10/20
1
10/20  
10/20Gilead Sciences, Inc. $GILD Expected to Announce Quarterly Sales of $6.31 Bil.. 
10/20SWING TRADE ALERT: Recent $GILD technical alerts: Doji - Bearish? plus 12 mor.. 
10/20Promotion at Gilead; trio of R&D excecs leave Moderna; and Bayer poaches .. 
10/20Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Ra.. 
10/20Gilead Slaps Mega-Price on Its Newly Approved CAR-T: Motley Fool  
10/20BRIEF-Gilead announces multiple scientific presentations  
10/20  
10/20Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Ra.. 
10/20Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Ra.. 
10/20$GILD Gilead Announces Multiple Scientific Presentations Demonstrating High C.. 
10/20Brainstorm Health: Thrive Global Samsung App, Gilead Cancer Gene Therapy, Lif..
1
10/20Gilead Sciences, Inc. $GILD Holdings Raised by GW Henssler & Associates L.. 
10/20Gilead Sciences, Inc. $GILD Holdings Raised by GW Henssler & Associates L.. 
10/20Gilead Sciences, Inc. $GILD Stake Raised by Cornerstone Capital Inc.  
10/20FDA approves Gilead cancer gene therapy; price set at $373,000
26
10/19[email protected] goes after $GILD on $373K price of Yescarta. Calls on Trump &..
5
10/19  
10/19  
10/19We discuss $GILD CAR-T approval, up next on @PowerLunch
1
10/19FDA approves Gilead cancer gene therapy; price set at $373,000
2
10/1935 Stocks Moving In Thursday's Mid-Day Session
3
10/1950 most #liquid, high #RelativeStrength #stocks in the #market $AABA $BABA $B.. 
10/19Gilead Kite's treatment becomes first FDA approved CAR-T therapy #KitePharma,.. 
10/19Gilead's Yescarta Cancer Treatment Approved, Some Analysts Shrug  
More tweets
Qtime:387
Financials ($)
Sales 2017 25 994 M
EBIT 2017 15 921 M
Net income 2017 10 622 M
Debt 2017 13 436 M
Yield 2017 2,60%
P/E ratio 2017 10,13
P/E ratio 2018 11,93
EV / Sales 2017 4,60x
EV / Sales 2018 5,11x
Capitalization 106 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 85,3 $
Spread / Average Target 5,0%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES13.41%106 054
REGENERON PHARMACEUTICALS17.95%46 395
VERTEX PHARMACEUTICALS109.90%38 985
ACTELION24.15%29 840
GENMAB13.21%12 865
EXELIXIS, INC.82.23%7 985